About argenx SE - American Depositary Shares (ARGX)
Argenx is a biotechnology company focused on developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company utilizes its proprietary platform to discover and create monoclonal antibodies that target specific proteins in the immune system to modulate its response. By exploring a diverse pipeline of clinical-stage candidates, Argenx aims to address unmet medical needs and improve patient outcomes through its cutting-edge approaches in immunology and therapeutic development. Read More
February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.
November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
